Driven by rising awareness of rare endocrine disorders, improvements in screening protocols for hypercortisolism, expanding orphan drug designations, and continuous innovations in targeted medical therapies and diagnostic assays, the global endocrinology and rare disease therapeutics sector is undergoing steady development. According to market research and industry intelligence...